These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36316762)

  • 1. Adherence patterns in naïve and prevalent use of infliximab and its biosimilar.
    Alanaeme CJ; Sarvesh S; Li CY; Bernatsky S; Curtis JR; Yun H
    BMC Rheumatol; 2022 Nov; 6(1):65. PubMed ID: 36316762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.
    Fitzgerald T; Melsheimer R; Lafeuille MH; Lefebvre P; Morrison L; Woodruff K; Lin I; Emond B
    Biologics; 2021; 15():1-15. PubMed ID: 33442230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.
    Bansback N; Curtis JR; Huang J; He Z; Evans M; Johansson T; Michaud K; Schmajuk G; Liao KP
    ACR Open Rheumatol; 2020 Feb; 2(2):79-83. PubMed ID: 32043831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data.
    Birck MG; Lukusa L; Choquette D; Boire G; Maksymowych WP; Singh H; Afif W; Bernatsky S
    BMC Rheumatol; 2024 Sep; 8(1):47. PubMed ID: 39343928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of rheumatology biosimilars in the absence of forced switching.
    Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
    Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar infliximab versus originator in Crohn's disease anti-TNF-α naïve and non-naïve patients.
    Kaniewska M; Rosolowski M; Moniuszko A; Rydzewska G
    Prz Gastroenterol; 2021; 16(3):207-212. PubMed ID: 34584581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018.
    Liu Y; Skup M; Yang M; Qi CZ; Wu EQ
    Adv Ther; 2022 Aug; 39(8):3711-3734. PubMed ID: 35737227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus.
    D'Amico F; Solitano V; Magro F; Olivera PA; Halfvarson J; Rubin D; Dignass A; Al Awadhi S; Kobayashi T; Queiroz NSF; Calvo M; Kotze PG; Ghosh S; Peyrin-Biroulet L; Danese S
    J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37834994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time.
    Overbeek JA; Kuiper JG; Bakker M; van den Bemt BJFB; Herings RMC
    Br J Clin Pharmacol; 2022 Feb; 88(4):1804-1810. PubMed ID: 34571570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study.
    Fisher A; Kim JD; Dormuth CR
    Gastroenterol Res Pract; 2023; 2023():2794220. PubMed ID: 36911254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study.
    Santoleri F; Abrate P; Pestrin L; Pasut E; Modesti G; Musicco F; Fulgenzio C; Zuzolo E; Pieri G; Roperti M; Gazzola P; Gambera M; Martignoni I; Montresor V; Guarino F; Grossi L; Di Fabio L; Roberti C; Spoltore C; Tinari G; De Rosa S; Giannini R; Langella R; Mingolla G; Piccoli M; Costantini A
    Glob Reg Health Technol Assess; 2024; 11():191-199. PubMed ID: 39397811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
    Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
    Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach to support implementation of biosimilars within a UK tertiary hospital.
    Saxby K; Sanghvi S; Bodalia PN; Ferner RE; Leandro M; Urquhart R; Sofat R
    Br J Clin Pharmacol; 2020 Jan; 86(1):23-28. PubMed ID: 31663154
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.